title: Emerging molecular targets for the treatment of asthma.
abstract: Current therapeutic approaches for the treatment of asthma have limitations in their ability to target all the features of the disease. Indeed, existing pharmacological asthma therapies are based on decades old strategies that were developed prior to the rapid growth in knowledge stemming from cell and molecular biology in the past decade. Thus, there is an unmet need for developing new drugs to target these features along with improved efficacy and safety. In the present review, the limitations of prevalent pharmacological asthma therapy are discussed briefly, and some explanations are suggested as to why new therapeutic targets are required to treat asthma, and finally directions for novel asthma therapies are proposed.
authors.affiliation: Department of Physiology, Faculty of Medicine University of Manitoba, 641-715 McDermot Ave Winnipeg, MB Canada. pawansharma96@yahoo.com
authors.forename: Pawan
authors.initials: P
authors.lastname: Sharma
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Halayko
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000378:metabolism*; D001993:Bronchodilator Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009841:Oligonucleotides / Q000378:metabolism / Q000627:therapeutic use; D014157:Transcription Factors / Q000037:antagonists & inhibitors
chemical_list: D001993:Bronchodilator Agents; D016207:Cytokines; D004791:Enzyme Inhibitors; D009841:Oligonucleotides; D014157:Transcription Factors